PG
TMO icon

Prostatis Group’s Thermo Fisher Scientific TMO Stock Holding History

Prostatis Group’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Sell
2,116
-698
-25% -$335K 0.25% 75
2026
Q1 		$1.38M Buy
2,814
+136
+5% +$73.8K 0.35% 63
2025
Q4 		$1.55M Buy
2,678
+287
+12% +$162K 0.37% 57
2025
Q3 		$1.16M Hold
2,391
– – 0.29% 71
2025
Q2 		$969K Sell
2,391
-33
-1% -$13.8K 0.28% 74
2025
Q1 		$1.21M Sell
2,424
-71
-3% -$38.5K 0.38% 56
2024
Q4 		$1.3M Buy
2,495
+28
+1% +$15.4K 0.38% 61
2024
Q3 		$1.53M Sell
2,467
-82
-3% -$48.5K 0.5% 51
2024
Q2 		$1.41M Sell
2,549
-82
-3% -$47K 0.49% 54
2024
Q1 		$1.53M Sell
2,631
-91
-3% -$51.1K 0.58% 49
2023
Q4 		$1.44M Sell
2,722
-107
-4% -$51.8K 0.6% 43
2023
Q3 		$1.43M Buy
2,829
+5
+0.2% +$2.66K 0.7% 33
2023
Q2 		$1.47M Hold
2,824
– – 0.69% 36
2023
Q1 		$1.63M Sell
2,824
-2
-0.1% -$1.13K 0.86% 28
2022
Q4 		$1.56M Sell
2,826
-1,278
-31% -$677K 0.95% 30
2022
Q3 		$2.08M Buy
4,104
+1,193
+41% +$668K 2.4% 13
2022
Q2 		$1.58M Sell
2,911
-1,431
-33% -$788K 2.47% 5
2022
Q1 		$2.56M Buy
4,342
+149
+4% +$85.6K 2.06% 20
2021
Q4 		$2.8M Buy
4,193
+1,000
+31% +$624K 1.72% 21
2021
Q3 		$1.82M Hold
3,193
– – 1.09% 29
2021
Q2 		$1.61M Buy
3,193
+4
+0.1% +$1.89K 1.1% 28
2021
Q1 		$1.46M Buy
3,189
+17
+0.5% +$8.11K 1.14% 24
2020
Q4 		$1.48M Sell
3,172
-649
-17% -$304K 1.24% 20
2020
Q3 		$1.69M Sell
3,821
-6
-0.2% -$2.48K 1.6% 19
2020
Q2 		$1.39M Sell
3,827
-2,347
-38% -$787K 2.79% 9
2020
Q1 		$1.75M Sell
6,174
-548
-8% -$173K 2.49% 16
2019
Q4 		$2.18M Buy
+6,722
New +$2.04M 1.97% 16

Other funds holding TMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Prostatis Group's TMO Position: Q2 2026 in Review

Prostatis Group reduced its Thermo Fisher Scientific (TMO) stake by 25% in Q2 2026, selling an estimated $335K and leaving 2,116 shares worth $1.06M. The position accounts for 0.25% of the portfolio, ranked #75.

Prostatis Group first reported a position in TMO in Q4 2019 and has held it in 27 quarters since. The position peaked at $2.8M in Q4 2021. 2,630 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Prostatis Group held 2,116 shares of Thermo Fisher Scientific worth $1.06M as of Q2 2026.
  • Prostatis Group sold 698 Thermo Fisher Scientific shares in Q2 2026, an estimated $335K.
  • Thermo Fisher Scientific made up 0.25% of Prostatis Group's portfolio in Q2 2026, its #75 holding.
  • Prostatis Group first reported a position in Thermo Fisher Scientific in Q4 2019 and has held it in 27 quarters since.
  • Prostatis Group's Thermo Fisher Scientific position peaked at $2.8M in Q4 2021.
  • 2,630 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Prostatis Group's 13F filing for Q2 2026, filed 14 Aug 2026.